Clinical Trials Logo

Filter by:
NCT ID: NCT02861235 Completed - Clinical trials for Myocardial Infarction

Comparison Between Myocardial Tomoscintigraphies Using a Semiconductor Camera or a Conventional Camera

DSPECT
Start date: November 2009
Phase: N/A
Study type: Interventional

Myocardial perfusion tomoscintigraphy is a routine medicine procedure to check for the presence and severity of abnormalities of myocardial perfusion, as well as the extension of infarction residua. However, actual imagery devices (gamma cameras) have low resolution and detection sensitivity. A new semiconductor camera has 8 to 10 time higher detection sensitivity and could allow proportionally diminishing injected activities or recording times. Only one pilot study has been recently published on this type of camera, the D.SPECT camera. This study will compare images recorded during 15 to 20 minutes by conventional cameras and 2 to 4 minutes by D.SPECT camera in patients doing tomoscintigraphy under usual conditions. The purpose is to demonstrate the equivalence of images recorded by two camera types for diagnostic information and the secondary purpose is to demonstrate the superiority of the D.SPECT camera in terms of image quality.

NCT ID: NCT02861222 Completed - Malignant Glioma Clinical Trials

Myocet® in Children With Relapsed or Refractory Non-brainstem Malignant Glioma

MYOCET
Start date: October 2010
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine the toxicity and tolerance of Myocet® in children and adolescents with refractory or relapsed malignant glioma, with a dose diminished of 20% of the dose recommended for adults and a dose recommended for adults, administered in single dose in 1-hour perfusion each 21 days. Other purposes are to determine the recommended dose of Myocet and to assess the response to drug. Pharmacokinetics of doxorubicin (free and encapsulated forms) and its metabolite doxorubicinol during 72 hours after Myocet administration will also be studied.

NCT ID: NCT02861092 Completed - Obesity Clinical Trials

Antibiotic-related Serious Adverse Events in Obese Patients Treated for Bone and Joint Infection

Start date: February 2015
Phase: N/A
Study type: Observational

It exists recommendations to get an optimal antibiotic treatment for bone and joint infection and prescription of antibiotics in the bone and joint infections on material meets certain obligations: the micro-organism must be known, the antibiotic therapy must be started in association, obtaining high plasma levels, use of molecules having good bone circulation. It is recommended to initially administer treatment with intravenous route and to propose an oral relay, under conditions. It is recommended to administer the antibiotic treatment for at least 6 weeks. The dosages of antibiotics are adapted to the weight of patients in order to respond to those recommendations. But little is known about the optimal dose of treatment to give to obese patients (BMI>=30) and the frequency of serious adverse events in these patients in which the dosage is then higher can be more important compared to non-obese patients. The aim of the study is then to evaluate the risk of occurrence of serious adverse events in obese patients and to identify risks factors. This study consists in a retrospective cohort of obese patients treated for a bone or joint infection and having had a serious adverse event. Several data are collected concerning: demographics data, treatment responsible of the serious adverse event (molecules, dosage, route), description of the serious adverse event, residual rate for vancomycin.

NCT ID: NCT02861014 Completed - Clinical trials for Multiple Sclerosis, Relapsing-Remitting

A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT)

Start date: September 9, 2016
Phase: Phase 3
Study type: Interventional

The purpose of this prospective, multicenter, open-label, efficacy, and safety study is to assess the efficacy and safety of ocrelizumab in participants with Relapsing Remitting Multiple Sclerosis (RRMS) who have had a suboptimal response to an adequate course of a Disease-Modifying Treatment (DMT). The study will consist of a Screening period (up to 4 weeks), an Open-label treatment period (96 weeks; with last dose administered at Week 72), and a Follow-up period of at least 2 years.

NCT ID: NCT02860923 Completed - Clinical trials for Hypothalamic Obesity

Efficacy and Safety of Exenatide in the Treatment of Hypothalamic Obesity After Craniopharyngioma Therapy

CRANIOEXE
Start date: January 11, 2017
Phase: Phase 3
Study type: Interventional

This hypothalamic obesity is associated with serious metabolic and psychosocial consequences. The purpose of the study is to compare the change of body weight after 6 months treatment with a lifestyle intervention + exenatide compare to the one after the same lifestyle intervention+ placebo in adults patients suffering from a hypothalamic obesity due to treatment of craniopharyngioma.

NCT ID: NCT02860884 Completed - Clinical trials for Non-alcoholic Fatty Liver Disease

Using Infrared Spectroscopy for Diagnosis Severity of Nonalcoholic Fatty Liver Disease

NASH
Start date: August 2014
Phase: N/A
Study type: Observational

The main objective of this study is to evaluate the ability of infrared spectroscopy to discriminate simple hepatic steatosis from NASH

NCT ID: NCT02860871 Completed - Joint Effusion Clinical Trials

Use of Infrared Spectroscopy in Septic Arthritis Diagnosis

SynoFAST
Start date: June 2014
Phase: N/A
Study type: Observational

The main objective of this study is to assess the ability of Fiber-optic Evanescent Wave Spectroscopy (FEWS) to discriminate synovial fluids samples of septic arthritis patients from other causes of joint effusion by analyzing ex vivo joint fluid samples collected during routine clinical care.

NCT ID: NCT02860793 Completed - Clinical trials for Acute Myeloid Leukemia

Role of PTK-7 in Acute Myeloid Leukemias

LAM-PTK7
Start date: January 2014
Phase: N/A
Study type: Interventional

The pseudo tyrosine kinase receptor 7 (PTK7) is an orphan tyrosine kinase receptor assigned to the planar cell polarity pathway. PTK7 is expressed in normal myeloid progenitors and CD34(+) CD38(-) bone marrow cells in humans. It is also expressed in acute myeloid leukemia (AML) and is mostly assigned to granulocytic lineage differentiation. In AML, PTK7 seems to convey promigratory and antiapoptotic signals into the cell and represents an independent prognosis factor of survival in patients treated with induction chemotherapy. This study aims at: - evaluating the impact of PTK7 expression on primary AML cells ex vivo - evaluating the diagnostic and prognostic value of a soluble form of PTK7

NCT ID: NCT02860767 Completed - Clinical trials for Prosthesis-Related Infections

Dosing of Antibiotics During Reimplantation of Infected Knee and Hip Prostheses

DOSOS
Start date: August 2016
Phase: N/A
Study type: Observational

The purpose of the study is to evaluate the concentrations of antibiotics used as empirical treatment in serum and periprosthetic tissues during reimplantation of infected hip and knee prostheses

NCT ID: NCT02860585 Completed - Breast Neoplasms Clinical Trials

Evaluation of Survival in Patients With Metastatic Breast Cancer Receiving High-dose Chemotherapy With Autologous Haematopoietic Stem Cell Transplantation

BREAST-HDCT
Start date: September 27, 2013
Phase: N/A
Study type: Observational

The objective of this study was to evaluate the outcome of patients affected with different subtypes of metastatic breast cancer following treatment with high-dose chemotherapy and autologous haematopoietic progenitor cell transplantation.